Pfizer Ends AstraZeneca Bid But The Tax Issues It Raised Live On — forbes.com

So another multi-billion dollar proposed merger between corporate giants is kaput.  Pfizer Pfizer announced on Monday it is abandoning its unsolicited bid to acquire British pharmaceutical company AstraZeneca AstraZeneca after the company rejected its offers four times. The why, when and what comes next of the deal’s demise can be found here and here and here. A less obvious ramification of the proposed deal, though, still must play out even though Pfizer is throwing in the towel: namely Pfizer’s bid infuriated many in Congress because it would allow the company to reincorporate in the U.K.

Read More